Levofloxacin

Chemical formula: C₁₈H₂₀FN₃O₄  Molecular mass: 361.368 g/mol  PubChem compound: 149096

Therapeutic indications

Levofloxacin is indicated for:

Community acquired pneumonia

Population group: only adults (18 years old or older)

at least one of
Community acquired pneumonia and additionally at least one of
Levofloxacin susceptible species
Levofloxacin susceptible species for which acquired resistance may be a problem

Group B streptococcal pneumonia
Group A streptococcal pneumonia
Rheumatic pneumonia
Acute bronchitis caused by Haemophilus influenzae
Haemophilus influenzae pneumonia
Mycoplasma pneumonia

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Complicated urinary tract infections

Population group: only adults (18 years old or older)

at least one of
Urinary tract infectious disease and additionally at least one of
Levofloxacin susceptible species
Levofloxacin susceptible species for which acquired resistance may be a problem

Acute genitourinary Chlamydia trachomatis infection
Chlamydia trachomatis urethritis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Pyelonephritis

Population group: only adults (18 years old or older)

Pyelonephritis and additionally at least one of
Levofloxacin susceptible species
Levofloxacin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Chronic prostatitis

Population group: men, only adults (18 years old or older)

Chronic prostatitis and additionally at least one of
Levofloxacin susceptible species
Levofloxacin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute bacterial sinusitis

Population group: only adults (18 years old or older)

Acute bacterial sinusitis and additionally at least one of
Levofloxacin susceptible species
Levofloxacin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Complicated skin and soft tissue infections

Population group: only adults (18 years old or older)

at least one of
Soft tissue infection and additionally at least one of
Levofloxacin susceptible species
Levofloxacin susceptible species for which acquired resistance may be a problem

Cutaneous anthrax
Meningitis caused by Streptococcus agalactiae
Haemophilus influenzae meningitis
Meningitis caused by Haemophilus influenzae type b

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Inhalational anthrax

Population group: only adults (18 years old or older)

Woolsorters' disease

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute exacerbation of chronic bronchitis

Population group: only adults (18 years old or older)

Acute exacerbation of chronic bronchitis and additionally at least one of
Levofloxacin susceptible species
Levofloxacin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Infective cystitis

Population group: only adults (18 years old or older)

Infective cystitis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Chronic pulmonary infections due to Pseudomonas aeruginosa in cystic fibrosis

Population group: only adults (18 - 65 years old)

Levofloxacin is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bacterial conjunctivitis, bacterial keratitis, infective uveitis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Levofloxacin eye drops are indicated for the topical treatment of bacterial external ocular infections in patients ≥1 year of age caused by levofloxacin susceptible microorganisms.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Levofloxacin is contraindicated in the following cases:

Epilepsy

Epilepsy

Pregnancy

Pregnancy

Lactation

Lactation

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: LEVOFLOXACIN Solution for infusion
Summary of Product Characteristics (SPC) 2019: LEVOFLOXACIN Film-coated tablet
Summary of Product Characteristics (SPC) 2019: QUINSAIR Nebuliser solution
Summary of Product Characteristics (SPC) 2020: OFTAQUIX Eye drops, solution
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈